Integrated Immunophenotyping and Gene Fusion Analysis in Pediatric Acute Lymphoblastic Leukemia: A Tertiary Care Hospital Study
DOI:
https://doi.org/10.21276/apalm.3574Keywords:
Acute lymphoblastic leukemia, Childhood,, Diagnostic, Gene-fusion, ImmunophenotypingAbstract
Background: Pediatric Acute Lymphoblastic Leukemia (ALL) is a complex hematologic malignancy characterized by the uncontrolled proliferation of immature lymphoid cells. Early diagnosis and precise classification are crucial for effective treatment and prognosis. This study aims to evaluate the utility of integrated immunophenotyping and gene fusion analysis in the diagnosis and stratification of pediatric ALL at a tertiary care hospital.
Methods: We analyzed clinical and laboratory data from a cohort of 50 pediatric ALL patients, applying immunophenotyping techniques to characterize cell surface markers and identifying relevant gene fusions associated with various subtypes of the disease. All statistical analysis was performed using SPSS v30, incorporating both parametric and non-parametric variables.
Result: Immunophenotyping of the 50 patients revealed that 90% had B-ALL, while the remaining 10% had T-ALL or mixed lineage phenotypes. Q-PCR analysis detected gene fusion positivity in 58% of cases, including key fusions associated with high-risk subtypes. These findings underscore the value of integrating immunophenotyping and molecular diagnostics for accurate classification and risk stratification in pediatric ALL. Our results highlight the role of these diagnostic tools in improving the accuracy of ALL classification, identifying high-risk genetic alterations, and guiding therapeutic decisions.
Conclusion: This study emphasizes the importance of combining immunophenotyping with molecular techniques for comprehensive diagnostic and prognostic assessments in pediatric ALL, offering a deeper understanding of the disease's pathogenesis and supporting personalized treatment approaches.
References
1. Patrick B, Hiroto I, Colleen A, Jill B, et al. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020. J Natl Compr Canc Netw 2020:18(1):81-112. doi:10.6004/jnccn.2020.0001
2. Brown PA, Shah B, Fathi A, Wieduwilt M, et al. NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017 Sep;15(9):1091-1102.
3. Praveen S, Tharageswari S, Nabhajit M. Flow Cytometry in the Diagnostic Laboratory Workup of Acute Lymphoblastic Leukemias. Ind J Med Paediatr Oncol 2023; 44:474-481.
4. Di Giuseppe JA, Wood BL. Applications of flow cytometric immunophenotyping in the diagnosis and post treatment monitoring of B and T lymphoblastic leukemia/lymphoma. Cytometry B Clin Cytom 2019;96(04):256-265.
5. Hiroto I, Charles G M. Pediatric acute lymphoblastic leukemia. Hematologica 2020 Sep 10 105(11):2524-2539. doi: 10.3324/haematol.2020.
6. Brown AL, Arts P, Carmichael CL, Babic M, et al. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv. 2020;4(6):1131-1144.
7. Halalsheh H, Abuirmeileh N, Rihani R, Bazzeh F, et al. Outcome of childhood acute lymphoblastic leukemia in Jordan. Pediatr. Blood Cancer. 2011:57:385-391.
8. Alecsa M-S, Moscalu M, Trandafir L-M, Ivanov A-V, et al. Outcomes in Pediatric Acute Lymphoblastic Leukemia-A Single-Center Romanian Experience. Journal of Clinical Medicine. 2020; 9(12):4052. https://doi.org/10.3390/jcm9124052
9. Pui C-H, Evans WE. A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia. Semin. Hematol. 2013;50:185-196. doi: 10.1053/j.seminhematol. 2013.06.007
10. Zhao XF, Wang HY, Zhao X, Cheng HC, et al. Study on Immunophenotypes and Gene of Acute Lymphoblastic Leukemia. 2018 Aug;26(4):947-952. Chinese. doi: 10.7534/j.issn.1009-2137.2018.04.001.
11. Weinberg OK, Seetharam M. Ren L, Alizadeh A, et al. Mixed phenotype acute leukemia. Am J Clin Pathol. 2014;142(6):803-808.
12. Charles NJ, Boyer DF. Mixed-phenotype acute leukemia: diagnostic criteria and pitfalls. Arch Pathol Lab Med. 2017;141(11):1462-1468.
13. Yang M, Tang Y, Zhu P, Lu H, et al. The advances of E2A-PBX1 fusion in B-cell acute lymphoblastic Leukaemia. Ann Hematol. 2024 Sep;103(9):3385-3398. doi: 10.1007/s00277-023-05595-7.
14. McLean TW, Ringold S, Neuberg D, Stegmaier K, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996;88(11):4252-8.
15. Loh ML, Goldwasser MA, Silverman LB, Poon WM, et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 2006:107(11):4508-13. doi: 10.1182/blood-2005-08-3451.
16. Norvilas R, Batiuskaite R, Dirse V, Semaskeviciene R, et al. Population-based targeted RNA sequencing reveals novel disease-related gene fusions in pediatric and adult T-ALL. Leukemia Research. Volume 116: 2022, 106825.
17. Mengmiao W, Siman H, Chaoling W, Tianmei W, et al. Co-expression of BCR-ABL1 and CBFB-MYH11 fusion genes in myeloid leukemia: three cases report and literature review. J Clin Hematol, 2023, 36(5): 360-365. doi:10.13201/j.issn.1004-2806.2023.05.012
18. Popescu R, Daascalescu A, Danaanilaa C, Ghiorghiu D, et al. Co-expression of the CBFB-MYH11 and BCR-ABL fusion genes in chronic myeloid leukaemia. Revista Romana de Medicina de Laborator. 2015:23(10).
19. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. Blood. 2016 Jul 21;128(3):462-463.
20. Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. Clin Adv Hematol Oncol. 2018 Mar 16(3):216-223.
21. Sanjeev K. Rajan K, Amit K, Ankur A, et al. Prevalence, clinical and haematological profile and outcome of BCR-ABL1-like acute lymphoblastic leukaemia in Indian children: A prospective observational study, Medical Journal Armed Forces India, 2024.
22. Foa R. Acute lymphoblastic leukemia: age and biology. Pediatr Rep. 2011;3 Suppl 2(Suppl 2):e2. doi: 10.4081/pr.2011.s2.e2.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Meenakumari Balaiah, Dougul Regis, Bhargavi K, Sariga Dhanasekar, Chandramouleeswari K
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
